Theravance Biopharma Inc (TBPH) Boosted by ValuEngine to Hold

Theravance Biopharma Inc (TBPH) Boosted by ValuEngine to Hold

Theravance Biopharma Inc (NASDAQ:TBPH) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

Several other equities analysts have also commented on TBPH. Needham & Company LLC reissued a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 28th. Piper Jaffray Companies restated an “overweight” rating and issued a $42.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, March 22nd. Finally, Leerink Swann set a $47.00 price objective on shares of Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 10th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Theravance Biopharma has an average rating of “Hold” and an average price target of $39.14.

Theravance Biopharma (TBPH) traded up 0.58% on Friday, reaching $38.04. The company’s stock had a trading volume of 104,493 shares. Theravance Biopharma has a 52 week low of $21.30 and a 52 week high of $41.48. The company has a 50 day moving average of $38.53 and a 200 day moving average of $33.59. The firm’s market capitalization is $2.03 billion.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.14) by $0.13. Theravance Biopharma had a negative return on equity of 61.09% and a negative net margin of 358.95%. The company had revenue of $3.09 million for the quarter, compared to analysts’ expectations of $5.07 million. On average, analysts forecast that Theravance Biopharma will post ($4.68) earnings per share for the current year.

In other Theravance Biopharma news, SVP Brett K. Haumann sold 13,576 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $31.52, for a total value of $427,915.52. Following the completion of the transaction, the senior vice president now directly owns 163,895 shares of the company’s stock, valued at $5,165,970.40. The sale was disclosed in a filing with the SEC, which is available at this link. 4.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TBPH. Teachers Advisors LLC boosted its position in shares of Theravance Biopharma by 19.2% in the fourth quarter. Teachers Advisors LLC now owns 69,563 shares of the biopharmaceutical company’s stock worth $2,218,000 after buying an additional 11,201 shares during the period. Norges Bank acquired a new position in shares of Theravance Biopharma during the fourth quarter worth $27,631,000. Opaleye Management Inc. acquired a new position in shares of Theravance Biopharma during the fourth quarter worth $5,043,000. Chescapmanager LLC acquired a new position in shares of Theravance Biopharma during the fourth quarter worth $8,676,000. Finally, Two Sigma Investments LP boosted its position in shares of Theravance Biopharma by 153.3% in the fourth quarter. Two Sigma Investments LP now owns 26,931 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 16,299 shares during the period. 68.01% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:TBPH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment